Optimal imaging time for Tc-99m phytate lymphoscintigraphy for sentinel lymph node mapping in patients with breast cancer

Objectives: Sentinel lymph node (SLN) sampling has become a standard practice in managing early-stage breast cancer. Lymphoscintigraphy is one of the major methods used. The radioactive tracer used in Taiwan is Tc-99m phytate. However, this agent is not commonly used around the world and the optimal...

Full description

Bibliographic Details
Main Authors: Ching-Chun Ho, Yu-Hung Chen, Shu-Hsin Liu, Hwa-Tsung Chen, Ming-Che Lee
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Tzu-Chi Medical Journal
Subjects:
Online Access:http://www.tcmjmed.com/article.asp?issn=1016-3190;year=2019;volume=31;issue=3;spage=163;epage=168;aulast=Ho
id doaj-6ef2d443b7be446f8a3dbc0adec33739
record_format Article
spelling doaj-6ef2d443b7be446f8a3dbc0adec337392020-11-25T01:09:25ZengWolters Kluwer Medknow PublicationsTzu-Chi Medical Journal1016-31902223-89562019-01-0131316316810.4103/tcmj.tcmj_88_18Optimal imaging time for Tc-99m phytate lymphoscintigraphy for sentinel lymph node mapping in patients with breast cancerChing-Chun HoYu-Hung ChenShu-Hsin LiuHwa-Tsung ChenMing-Che LeeObjectives: Sentinel lymph node (SLN) sampling has become a standard practice in managing early-stage breast cancer. Lymphoscintigraphy is one of the major methods used. The radioactive tracer used in Taiwan is Tc-99m phytate. However, this agent is not commonly used around the world and the optimal imaging time has not been studied. Thus, we investigated the optimal imaging time of Tc-99m phytate lymphoscintigraphy for SLN mapping in patients with breast cancer. Materials and Methods: We retrospectively reviewed SLN Tc-99m phytate lymphoscintigraphies in 135 patients with breast cancer between August 2013 and November 2017. The time for the first SLN to be visualized after radiotracer injection was recorded to determine the optimal imaging time. If no SLN was identified on imaging, the scan was continued to 60 min. We also recorded the presurgical technical and clinical factors to analyze the risk factors for nonvisualization of SLN. Each patient's postoperative axillary lymph node status was also recorded. Results: Axillary SLNs were identified on imaging in 94.8% of the patients. All first SLNs presented within 30 min. In 6 of 7 patients with negative imaging, SLNs were identified during surgery using either blue dye or a hand-held gamma probe. Nonvisualization of SLNs on lymphoscintigraphy was significantly associated with a lower injection dose (1.0 mCi vs. 2.0 mCi), 4-injection protocol (compared to 2-injection), and injection around an outer upper quadrant tumor. In addition, patients with axillary lymph node metastasis had a higher percentage of SLN image mapping failure, with a marginally significant difference. Conclusion: Based on our study, 30 min after Tc-99m phytate injection is the optimal time for lymphoscintigraphy and delayed imaging beyond 30 min is not necessary. In addition, a lower injection dose, the 4-injection method, and an injection near the outer upper quadrant tumor should be avoided to minimize nonvisualization of SLNs.http://www.tcmjmed.com/article.asp?issn=1016-3190;year=2019;volume=31;issue=3;spage=163;epage=168;aulast=HoBreast cancerLymphoscintigraphyPhytateSentinel lymph node
collection DOAJ
language English
format Article
sources DOAJ
author Ching-Chun Ho
Yu-Hung Chen
Shu-Hsin Liu
Hwa-Tsung Chen
Ming-Che Lee
spellingShingle Ching-Chun Ho
Yu-Hung Chen
Shu-Hsin Liu
Hwa-Tsung Chen
Ming-Che Lee
Optimal imaging time for Tc-99m phytate lymphoscintigraphy for sentinel lymph node mapping in patients with breast cancer
Tzu-Chi Medical Journal
Breast cancer
Lymphoscintigraphy
Phytate
Sentinel lymph node
author_facet Ching-Chun Ho
Yu-Hung Chen
Shu-Hsin Liu
Hwa-Tsung Chen
Ming-Che Lee
author_sort Ching-Chun Ho
title Optimal imaging time for Tc-99m phytate lymphoscintigraphy for sentinel lymph node mapping in patients with breast cancer
title_short Optimal imaging time for Tc-99m phytate lymphoscintigraphy for sentinel lymph node mapping in patients with breast cancer
title_full Optimal imaging time for Tc-99m phytate lymphoscintigraphy for sentinel lymph node mapping in patients with breast cancer
title_fullStr Optimal imaging time for Tc-99m phytate lymphoscintigraphy for sentinel lymph node mapping in patients with breast cancer
title_full_unstemmed Optimal imaging time for Tc-99m phytate lymphoscintigraphy for sentinel lymph node mapping in patients with breast cancer
title_sort optimal imaging time for tc-99m phytate lymphoscintigraphy for sentinel lymph node mapping in patients with breast cancer
publisher Wolters Kluwer Medknow Publications
series Tzu-Chi Medical Journal
issn 1016-3190
2223-8956
publishDate 2019-01-01
description Objectives: Sentinel lymph node (SLN) sampling has become a standard practice in managing early-stage breast cancer. Lymphoscintigraphy is one of the major methods used. The radioactive tracer used in Taiwan is Tc-99m phytate. However, this agent is not commonly used around the world and the optimal imaging time has not been studied. Thus, we investigated the optimal imaging time of Tc-99m phytate lymphoscintigraphy for SLN mapping in patients with breast cancer. Materials and Methods: We retrospectively reviewed SLN Tc-99m phytate lymphoscintigraphies in 135 patients with breast cancer between August 2013 and November 2017. The time for the first SLN to be visualized after radiotracer injection was recorded to determine the optimal imaging time. If no SLN was identified on imaging, the scan was continued to 60 min. We also recorded the presurgical technical and clinical factors to analyze the risk factors for nonvisualization of SLN. Each patient's postoperative axillary lymph node status was also recorded. Results: Axillary SLNs were identified on imaging in 94.8% of the patients. All first SLNs presented within 30 min. In 6 of 7 patients with negative imaging, SLNs were identified during surgery using either blue dye or a hand-held gamma probe. Nonvisualization of SLNs on lymphoscintigraphy was significantly associated with a lower injection dose (1.0 mCi vs. 2.0 mCi), 4-injection protocol (compared to 2-injection), and injection around an outer upper quadrant tumor. In addition, patients with axillary lymph node metastasis had a higher percentage of SLN image mapping failure, with a marginally significant difference. Conclusion: Based on our study, 30 min after Tc-99m phytate injection is the optimal time for lymphoscintigraphy and delayed imaging beyond 30 min is not necessary. In addition, a lower injection dose, the 4-injection method, and an injection near the outer upper quadrant tumor should be avoided to minimize nonvisualization of SLNs.
topic Breast cancer
Lymphoscintigraphy
Phytate
Sentinel lymph node
url http://www.tcmjmed.com/article.asp?issn=1016-3190;year=2019;volume=31;issue=3;spage=163;epage=168;aulast=Ho
work_keys_str_mv AT chingchunho optimalimagingtimefortc99mphytatelymphoscintigraphyforsentinellymphnodemappinginpatientswithbreastcancer
AT yuhungchen optimalimagingtimefortc99mphytatelymphoscintigraphyforsentinellymphnodemappinginpatientswithbreastcancer
AT shuhsinliu optimalimagingtimefortc99mphytatelymphoscintigraphyforsentinellymphnodemappinginpatientswithbreastcancer
AT hwatsungchen optimalimagingtimefortc99mphytatelymphoscintigraphyforsentinellymphnodemappinginpatientswithbreastcancer
AT mingchelee optimalimagingtimefortc99mphytatelymphoscintigraphyforsentinellymphnodemappinginpatientswithbreastcancer
_version_ 1725179006883463168